NIKKEI 225
39,043.06 +425.96 (+1.10%) HANG SENG
18,874.05 -321.55 (-1.68%) CRUDE OIL
76.93 -0.64 (-0.83%) GOLD FUTURES
2,369.00 -23.90 (-1.00%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,492.73 -400.00 (-0.73%)
Fresenius Medical Care AG & Co. KGaA (FME.BE)
| Previous close | 39.63 |
| Open | 39.59 |
| Bid | 38.44 x 30000 |
| Ask | 38.98 x 50000 |
| Day's range | 38.63 - 39.59 |
| 52-week range | 31.04 - 49.52 |
| Volume | |
| Avg. volume | 189 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 30 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireFresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024
Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the presentation of nearly 40 company-affiliated research abstracts at the 61st European Renal Association (ERA) Congress, taking place May 23-26, 2024, in Stockholm, Sweden and virtually.
- PR Newswire
Fresenius Medical Care Annual General Meeting: Company makes significant progress in its Transformation Efforts and confirms its ambitious 2024 Growth Targets
Fresenius Medical Care (FME), the global leader in providing products and services for people with kidney diseases, is executing its strategic turnaround plan and is well on track to achieve its goals for 2024.
- Reuters
Fresenius Medical sees up to 2% US dialysis growth by year-end
The number of kidney dialysis sessions provided by Fresenius Medical Care in its top market, the United States, could rise by as much as 2% by the end of the year, its CEO said, as the impact of the pandemic on patients fades. Fresenius Medical Care is the world's largest kidney dialysis company, and the fallout from the pandemic - which led to an increase in deaths among patients - has weighed heavily on its shares. Fresenius Medical earlier this year said it anticipated a return to treatment volume growth in the U.S. over the course of 2024, as it slowly recovers from COVID-related deaths among its patients, many of whom suffer from a range of cardiovascular conditions.
